Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Creative Commons License

Yozgat A. K., LEBLEBİSATAN G., AKBAYRAM S., Ozel S. C., Karakas Z., ERDURAN E., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.3, pp.139-144, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.4274/tjh.galenos.2020.2019.0380
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.139-144
  • Keywords: Immune thrombocytopenia, Eltrombopag, Iron deficiency, QUALITY-OF-LIFE, DOUBLE-BLIND, THROMBOPOIETIN, ROMIPLOSTIM, ADULTS
  • Dokuz Eylül University Affiliated: Yes


Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.